Akero Therapeutics’ Product Efruxifermin Demonstrates Strong Positive Results in NASH Patients

Akero Therapeutics Efruxifermin Positive Results in NASH

Akero Therapeutics (AKRO) results of a 16-week analysis of secondary and exploratory endpoints in Phase 2a BALANCED study of its product efruxifermin (EFX), formerly known as AKR-001, in patients with nonalcoholic steatohepatitis (NASH) are beating everybody’s expectations, including Akero Therapeutics.   

Of the 40 responders, the firm observed that 48% achieved at least a one-stage improvement in fibrosis without worsening of NAFLD activity score (NAS) and 28% achieved at least a two-stage improvement in fibrosis.

Leave a Reply